Griffithazanone A exhibits significant anti-inflammatory properties by inhibiting the production of pro-inflammatory mediators such as nitric oxide and prostaglandin E2 in activated macrophages. It achieves this by suppressing the expression of key enzymes like inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). Due to this mechanism, it is studied for potential use in managing chronic inflammatory diseases, including arthritis and inflammatory bowel disease. Additionally, it shows moderate antioxidant activity, which may contribute to its overall protective effects in cellular models of oxidative stress. Its natural origin and bioactivity make it a candidate for development as a phytochemical-based therapeutic agent or nutraceutical.